Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02818920 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Pembrolizumab
A Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Neal Ready MD PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 3
- Study locations
NCT02818920: Completed Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Neal Ready MD PhD.
NCT02818920 is a Phase 2 study of Non-Small-Cell Lung Carcinoma that has completed, run by Neal Ready MD PhD. The registered enrollment target is 35 participants, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02818920, a Phase 2 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Neal Ready MD PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 3
- Study locations
Study Summary
This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer cells. Pembrolizumab has been approved for the treatment of advanced lung cancer, but is investigational in this setting.
Primary Outcome
A patient who meets the eligibility criteria, has received at least 1 dose of pembrolizumab, and undergone surgery in the window of 29-56 days after initiation of pembrolizumab is considered surgically feasible. All other situations are considered infeasible.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-01 |
| Est. Completion | 2024-06-20 |
| Phase | Phase 2 |
What the finished NCT02818920 record still lists
NCT02818920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02818920 reports a single indexed study location in Minnesota, New Hampshire, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02818920 about?
NCT02818920 is a clinical study titled "Neoadjuvant Pembrolizumab". This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may...
What is the current status of trial NCT02818920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2017-01. Estimated completion is 2024-06-20.
What conditions does trial NCT02818920 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT02818920?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02818920?
This trial is sponsored by Neal Ready MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02818920 being conducted?
This trial has 3 study locations across Minnesota, New Hampshire, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02818920's enrollment target sits among peer trials
35 27th of 30 higher than 3 of 30 other Non-Small-Cell Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small-Cell Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
COMPLETED · Phase 2
-
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
COMPLETED · Phase 2
-
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
COMPLETED · Phase 2
-
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia